TY  - JOUR
AU  - Zavišić, Gordana
AU  - Ristić, Slavica
AU  - Rikalović, Milena
AU  - Petković, Branka
AU  - Janković, Drina
AU  - Vukadinović, Aleksandar
AU  - Petričević, Saša
PY  - 2022
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10379
AB  - The present study aimed to examine the effect of Lactobacillus rhamnosus Rosell 11 and Lactobacillus helveticus Rosell 52 on glucose (blood level and tolerance), lipids (cholesterol and triglycerides), transaminases (AST and ALT), ALP, urea, and creatinine, along with body weight, food intake, liquid consumption, and gross pathology in a mouse model of metabolic syndrome. Male C57BL/6J mice were fed a high-fat high-sucrose diet and treated by oral gavage with a probiotic mixture in three different concentrations (107, 108, and 109 CFU/mL) once daily for 2 months. Probiotic supplementation, particularly at a concentration of 109 CFU, significantly decreased blood glucose and serum triglyceride levels, improved glucose tolerance, and promoted body weight loss in mice fed a high-fat high-sucrose diet. According to the obtained results, probiotic supplementation is useful for controlling glucose and triglyceride levels and could be used as an adjunctive therapeutic approach in patients with metabolic syndrome.
T2  - Journal of Functional Foods
T1  - Beneficial effects of probiotic supplementation on glucose and triglycerides in a mouse model of metabolic syndrome
VL  - 95
SP  - 105167
DO  - 10.1016/j.jff.2022.105167
ER  - 

@article{
author = "Zavišić, Gordana and Ristić, Slavica and Rikalović, Milena and Petković, Branka and Janković, Drina and Vukadinović, Aleksandar and Petričević, Saša",
year = "2022",
abstract = "The present study aimed to examine the effect of Lactobacillus rhamnosus Rosell 11 and Lactobacillus helveticus Rosell 52 on glucose (blood level and tolerance), lipids (cholesterol and triglycerides), transaminases (AST and ALT), ALP, urea, and creatinine, along with body weight, food intake, liquid consumption, and gross pathology in a mouse model of metabolic syndrome. Male C57BL/6J mice were fed a high-fat high-sucrose diet and treated by oral gavage with a probiotic mixture in three different concentrations (107, 108, and 109 CFU/mL) once daily for 2 months. Probiotic supplementation, particularly at a concentration of 109 CFU, significantly decreased blood glucose and serum triglyceride levels, improved glucose tolerance, and promoted body weight loss in mice fed a high-fat high-sucrose diet. According to the obtained results, probiotic supplementation is useful for controlling glucose and triglyceride levels and could be used as an adjunctive therapeutic approach in patients with metabolic syndrome.",
journal = "Journal of Functional Foods",
title = "Beneficial effects of probiotic supplementation on glucose and triglycerides in a mouse model of metabolic syndrome",
volume = "95",
pages = "105167",
doi = "10.1016/j.jff.2022.105167"
}

Zavišić, G., Ristić, S., Rikalović, M., Petković, B., Janković, D., Vukadinović, A.,& Petričević, S.. (2022). Beneficial effects of probiotic supplementation on glucose and triglycerides in a mouse model of metabolic syndrome. in Journal of Functional Foods, 95, 105167.
https://doi.org/10.1016/j.jff.2022.105167

Zavišić G, Ristić S, Rikalović M, Petković B, Janković D, Vukadinović A, Petričević S. Beneficial effects of probiotic supplementation on glucose and triglycerides in a mouse model of metabolic syndrome. in Journal of Functional Foods. 2022;95:105167.
doi:10.1016/j.jff.2022.105167 .

Zavišić, Gordana, Ristić, Slavica, Rikalović, Milena, Petković, Branka, Janković, Drina, Vukadinović, Aleksandar, Petričević, Saša, "Beneficial effects of probiotic supplementation on glucose and triglycerides in a mouse model of metabolic syndrome" in Journal of Functional Foods, 95 (2022):105167,
https://doi.org/10.1016/j.jff.2022.105167 . .

TY  - JOUR
AU  - Milanović, Zorana
AU  - Janković, Drina
AU  - Vranješ-Đurić, Sanja
AU  - Radović, Magdalena
AU  - Prijović, Željko
AU  - Zavišić, Gordana
AU  - Perić, Marko
AU  - Stanković, Dalibor M.
AU  - Mirković, Marija D.
PY  - 2021
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/9960
AB  - Purpose Recent studies with doxycycline as adjuvant therapy to conventional chemotherapy have shown promising results in cancer therapy. The current study aimed to examine the capability of 177Lu-labeled tetracycline ligand, doxycycline hyclate, to use as an anticancer agent.Materials and methods Doxycycline was radiolabeled with beta-emitting radioisotope 177Lu. Complex formation and its interaction with DNA were investigated electrochemically. Binding of 177Lu-doxycycline to CT 26 cell line was done. Biodistribution of 177Lu-doxycycline was examined in healthy Wistar rats and CT26 colon carcinoma tumor-bearing mice by i.v. and i.p. administration, respectively.Results Doxycycline hyclate was successfully radiolabeled with 177Lu in high radiolabeling yield (>99%). The radiolabeled complex was stable in vitro in saline and human serum over 72 h. Non-radioactive Lu-doxycycline complex formation was demonstrated electrochemically as well. Intercalative interactions of the doxycycline and Lu-doxycycline with DNA were proved using simultaneously spectrophotometric and electrochemical methods. The binding of the radiolabeled complex with plasma proteins was 4.0 ± 0.4%. The partition coefficient showed the lipophilic nature of the complex similar to the free ligand. The binding curve demonstrates binding from 0.1 nM concentrations of 177Lu-doxycycline, with half-binding estimated ∼100 nM. Biodistribution studies of 177Lu-doxycycline in CT26 colon tumor-bearing mice showed a satisfactory accumulation rate in the tumor (2.88 ± 0.85% ID/g) 3 h after intraperitoneal injection. Both the hepatobiliary system and the urinary system were prominent as excretory routes of the radiolabeled complex.Conclusion Considering obtained results, 177Lu-doxycycline complex, due to its excellent electrochemical and biological characteristics, with emphasis on the binding ability to DNA via intercalative interaction as well as significant accumulation in the tumor, is suitable for further in vivo studies to investigate its potential use in cancer treatment.
T2  - International Journal of Radiation Biology
T1  - 177Lu-doxycycline as potential radiopharmaceutical: electrochemical characterization, radiolabeling, and biodistribution in tumor-bearing mice
SP  - 1
EP  - 9
DO  - 10.1080/09553002.2021.1976864
ER  - 

@article{
author = "Milanović, Zorana and Janković, Drina and Vranješ-Đurić, Sanja and Radović, Magdalena and Prijović, Željko and Zavišić, Gordana and Perić, Marko and Stanković, Dalibor M. and Mirković, Marija D.",
year = "2021",
abstract = "Purpose Recent studies with doxycycline as adjuvant therapy to conventional chemotherapy have shown promising results in cancer therapy. The current study aimed to examine the capability of 177Lu-labeled tetracycline ligand, doxycycline hyclate, to use as an anticancer agent.Materials and methods Doxycycline was radiolabeled with beta-emitting radioisotope 177Lu. Complex formation and its interaction with DNA were investigated electrochemically. Binding of 177Lu-doxycycline to CT 26 cell line was done. Biodistribution of 177Lu-doxycycline was examined in healthy Wistar rats and CT26 colon carcinoma tumor-bearing mice by i.v. and i.p. administration, respectively.Results Doxycycline hyclate was successfully radiolabeled with 177Lu in high radiolabeling yield (>99%). The radiolabeled complex was stable in vitro in saline and human serum over 72 h. Non-radioactive Lu-doxycycline complex formation was demonstrated electrochemically as well. Intercalative interactions of the doxycycline and Lu-doxycycline with DNA were proved using simultaneously spectrophotometric and electrochemical methods. The binding of the radiolabeled complex with plasma proteins was 4.0 ± 0.4%. The partition coefficient showed the lipophilic nature of the complex similar to the free ligand. The binding curve demonstrates binding from 0.1 nM concentrations of 177Lu-doxycycline, with half-binding estimated ∼100 nM. Biodistribution studies of 177Lu-doxycycline in CT26 colon tumor-bearing mice showed a satisfactory accumulation rate in the tumor (2.88 ± 0.85% ID/g) 3 h after intraperitoneal injection. Both the hepatobiliary system and the urinary system were prominent as excretory routes of the radiolabeled complex.Conclusion Considering obtained results, 177Lu-doxycycline complex, due to its excellent electrochemical and biological characteristics, with emphasis on the binding ability to DNA via intercalative interaction as well as significant accumulation in the tumor, is suitable for further in vivo studies to investigate its potential use in cancer treatment.",
journal = "International Journal of Radiation Biology",
title = "177Lu-doxycycline as potential radiopharmaceutical: electrochemical characterization, radiolabeling, and biodistribution in tumor-bearing mice",
pages = "1-9",
doi = "10.1080/09553002.2021.1976864"
}

Milanović, Z., Janković, D., Vranješ-Đurić, S., Radović, M., Prijović, Ž., Zavišić, G., Perić, M., Stanković, D. M.,& Mirković, M. D.. (2021). 177Lu-doxycycline as potential radiopharmaceutical: electrochemical characterization, radiolabeling, and biodistribution in tumor-bearing mice. in International Journal of Radiation Biology, 1-9.
https://doi.org/10.1080/09553002.2021.1976864

Milanović Z, Janković D, Vranješ-Đurić S, Radović M, Prijović Ž, Zavišić G, Perić M, Stanković DM, Mirković MD. 177Lu-doxycycline as potential radiopharmaceutical: electrochemical characterization, radiolabeling, and biodistribution in tumor-bearing mice. in International Journal of Radiation Biology. 2021;:1-9.
doi:10.1080/09553002.2021.1976864 .

Milanović, Zorana, Janković, Drina, Vranješ-Đurić, Sanja, Radović, Magdalena, Prijović, Željko, Zavišić, Gordana, Perić, Marko, Stanković, Dalibor M., Mirković, Marija D., "177Lu-doxycycline as potential radiopharmaceutical: electrochemical characterization, radiolabeling, and biodistribution in tumor-bearing mice" in International Journal of Radiation Biology (2021):1-9,
https://doi.org/10.1080/09553002.2021.1976864 . .